J&J Drug Combo Stops Lung Cancer Spread for Longer

Published on September 6, 2023

Johnson & Johnson said on Wednesday its combination drug helped increase the duration of no progress in a type of non small-cell lung cancer in patients. The therapy met the main goals of the study that tested a combination of antibody treatment Rybrevant and experimental…

Read Full Article (External Site)